Enfortumab vedotin targets nectin-4 for internalization; once inside, MMAE binds the vinca site on beta-tubulin to inhibit microtubule polymerization and trigger G2/M arrest and apoptosis. Beta-tubulin expression alone is not sufficient for targeting or killing.